Literature DB >> 16301653

Human cytomegalovirus encodes an MHC class I-like molecule (UL142) that functions to inhibit NK cell lysis.

Mark R Wills1, Omodele Ashiru, Matthew B Reeves, Georgina Okecha, John Trowsdale, Peter Tomasec, Gavin W G Wilkinson, John Sinclair, J G Patrick Sissons.   

Abstract

Clinical and low passage strains of human CMV (HCMV) encode an additional MHC class I-related molecule UL142, in addition to the previously described UL18. The UL142 open reading frame is encoded within the ULb' region which is missing from a number of common high passage laboratory strains. Cells expressing UL142 following transfection, and fibroblasts infected with a recombinant adenovirus-expressing UL142, were used to screen both polyclonal NK cells and NK cell clones, in a completely autologous system. Analysis of 100 NK cell clones derived from five donors, revealed 23 clones that were inhibited by fibroblasts expressing UL142 alone. Small-interfering RNA-mediated knockdown of UL142 mRNA expression in HCMV-infected cells resulted in increased sensitivity to lysis. From these data we conclude that UL142 is a novel HCMV-encoded MHC class I-related molecule which inhibits NK cell killing in a clonally dependent manner.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16301653     DOI: 10.4049/jimmunol.175.11.7457

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  67 in total

1.  Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function.

Authors:  Bree Foley; Sarah Cooley; Michael R Verneris; Michelle Pitt; Julie Curtsinger; Xianghua Luo; Sandra Lopez-Vergès; Lewis L Lanier; Daniel Weisdorf; Jeffrey S Miller
Journal:  Blood       Date:  2011-12-16       Impact factor: 22.113

2.  Can we build it better? Using BAC genetics to engineer more effective cytomegalovirus vaccines.

Authors:  Mark R Schleiss
Journal:  J Clin Invest       Date:  2010-11-22       Impact factor: 14.808

3.  Structure of UL18, a peptide-binding viral MHC mimic, bound to a host inhibitory receptor.

Authors:  Zhiru Yang; Pamela J Bjorkman
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-15       Impact factor: 11.205

Review 4.  An integrated view of the regulation of NKG2D ligands.

Authors:  Noam Stern-Ginossar; Ofer Mandelboim
Journal:  Immunology       Date:  2009-09       Impact factor: 7.397

Review 5.  Congenital cytomegalovirus infection: molecular mechanisms mediating viral pathogenesis.

Authors:  Mark R Schleiss
Journal:  Infect Disord Drug Targets       Date:  2011-10

6.  Identification of TRIM23 as a cofactor involved in the regulation of NF-kappaB by human cytomegalovirus.

Authors:  Emma Poole; Ian Groves; Andrew MacDonald; Yin Pang; Antonio Alcami; John Sinclair
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

7.  Coding potential of UL/b' from the initial source of rhesus cytomegalovirus Strain 68-1.

Authors:  Rachel B Gill; J Jason Bowman; Tammy Krogmann; Kurt Wollenberg; David M Asher; Jeffrey I Cohen
Journal:  Virology       Date:  2013-10-02       Impact factor: 3.616

8.  Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands.

Authors:  Lola Fernández-Messina; Omodele Ashiru; Philippe Boutet; Sonia Agüera-González; Jeremy N Skepper; Hugh T Reyburn; Mar Valés-Gómez
Journal:  J Biol Chem       Date:  2010-01-14       Impact factor: 5.157

Review 9.  Immunogenetics of the NKG2D ligand gene family.

Authors:  Masanori Kasahara; Shigeru Yoshida
Journal:  Immunogenetics       Date:  2012-07-29       Impact factor: 2.846

10.  Human cytomegalovirus pUL10 interacts with leukocytes and impairs TCR-mediated T-cell activation.

Authors:  Luca Bruno; Mirko Cortese; Giuseppina Monda; Michela Gentile; Stefano Calò; Francesca Schiavetti; Luisanna Zedda; Elena Cattaneo; Diego Piccioli; Mary Schaefer; Eugenio Notomista; Domenico Maione; Andrea Carfì; Marcello Merola; Yasushi Uematsu
Journal:  Immunol Cell Biol       Date:  2016-05-19       Impact factor: 5.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.